DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Carbamazepine Treatment for Cocaine Dependence - 5

Information source: University of Pennsylvania
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cocaine-Related Disorders

Intervention: Carbamazepine (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: University of Pennsylvania

Official(s) and/or principal investigator(s):
James Cornish, M.D., Principal Investigator, Affiliation: University of Pennsylvania

Summary

The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.

Clinical Details

Official title: Carbamazepine Treatment for Cocaine Dependence

Study design: Primary Purpose: Treatment

Eligibility

Minimum age: 21 Years. Maximum age: 51 Years. Gender(s): Both.

Criteria:

Please contact site for information.

Locations and Contacts

University of Pennsylvania, Philadelphia, Pennsylvania 19104 6178, United States
Additional Information

Related publications:

Cornish JW, Maany I, Fudala PJ, Neal S, Poole SA, Volpicelli P, O'Brien CP. Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend. 1995 Jun;38(3):221-7.

Starting date: January 1991
Last updated: May 26, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017